June 19, 2008 - ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, today announced that the company has signed a research agreement with George Mason University for the development of a blood test to detect small cell lung cancer and pancreatic cancer using IMUC's monoclonal antibody technology. The blood-based test would be designed to look for certain markers for the cancers potentially allowing for early detection of these cancers as well as assisting the selection of patients most likely to respond to the company's monoclonal antibody therapy, ICT-109... ImmunoCellular Therapeutics' Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
June
(39)
- M. D. Anderson and Aureon Laboratories : to Evalua...
- Aradigm : Phase 2 Study of Inhaled Liposomal Cipro...
- Alnylam and Kyowa Hakko : Alliance for the Develop...
- Altus Pharmaceuticals : Last Patient Visit Of Triz...
- Transave : POSITIVE PHASE II RESULTS FOR ONCE-DAIL...
- Gilead : Interim 12-Month Phase III Study Results ...
- Pharmacopeia and GlaxoSmithKline Collaboration : a...
- Banner Pharmacaps : FDA Approval for Amantadine S...
- ImmunoCellular Therapeutics : Research Agreement w...
- Vitrolife : STEEN Solution approved for sales in A...
- Pharmaxis : Special Protocol Assessment with FDA f...
- FASgen : Production and Investment Agreement with ...
- Vall d’Hebron University Hospital and Cyclacel Pha...
- Ikaria : INOFLO (NITRIC OXIDE) FOR INHALATION TO B...
- Boehringer Ingelheim : to acquire Actimis Pharmace...
- SkyePharma : Second Flutiform Phase III Efficacy S...
- ALK-Abelló : GRAZAX® Demonstrates Significant Redu...
- Anesiva and Transcription Factor Therapeutics : Li...
- AstraZeneca submits an sNDA for SYMBICORT® for the...
- Critical Therapeutics : Phase II Clinical Trial fo...
- Novavax : Proprietary Method to Create SARS Vaccin...
- Jennerex Promising Results from Cancer Clinical T...
- Emphasys Medical : VENT Clinical Trial Data at ATS...
- Angiotech : completion of Bio-Seal clinical trial ...
- Bayer HealthCare and Nektar Therapeutics : Amikaci...
- Lilly : Study Showed ALIMTA (pemetrexed for injec...
- GlaxoSmithKline : New data for pazopanib – GSK’s l...
- Rosetta Genomics and M. D. Anderson to Develop a M...
- GlaxoSmithKline : New data on MAGE-A3 cancer immu...
- Pulmo BioTech : Details of the Methodology for its...
- MDS Pharma Services : Therapeutic Focus on Respira...
- DEY : Concomitant Use of Nebulized Formoterol Fuma...
- Almirall & Forest : Positive Results of Clinical S...
- Basilea Pharmaceutica : Ceftobiprole shows high cu...
- Perceptronix Medical : Early Detection Brings Hope
- TeraRecon iNtuition : at the Stanford MDCT face-of...
- Critical Outcome Technologies : Amalgamation With ...
- Dako : unique package of RTU antibodies for cancer...
- Med BioGene and University Health Network : Collab...
-
▼
June
(39)
Jun 20, 2008
ImmunoCellular Therapeutics : Research Agreement with George Mason University for Detection of Certain Cancers
Libellés :
ImmunoCellular Therapeutics,
Lung Cancer